Exon-Level Biomarker Analysis for Oocyte Competence Prediction
Solution Overview
Problem
Current methods for evaluating oocyte competence in assisted reproduction technologies (ART) face challenges due to variability in gene expression influenced by patient-specific characteristics and differing experimental conditions, leading to inconsistent identification of biomarker genes for predicting pregnancy outcomes.
Innovation Solution
A novel method involving exon-level analysis of cumulus cell gene expression, using live birth and embryo development as endpoints, and intra-patient comparisons to identify biomarker genes and develop predictive models for oocyte competence, which includes genes like EFNB2, CAMK1D, and STC1, and their splice variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional gene expression analysis methods are used to evaluate oocyte competence, then the assessment can be performed, but the results show high variability due to patient-specific characteristics and experimental conditions, leading to inconsistent biomarker identification
Solution Approach 1:
The patent segments the gene expression analysis at the exon level rather than analyzing entire genes. This segmentation allows for more precise identification of differential expression patterns specific to oocyte competence, reducing the noise from patient-specific variations and improving both measurement precision and reliability of biomarker identification
Solution Approach 2:
The patent changes the analysis parameter from whole-gene expression levels to exon-level expression patterns. This parameter change enables detection of subtle differential expression that is specific to competent oocytes, thereby improving prediction accuracy while the focus on specific exons reduces variability from external factors
2Measurement precision
If exon-level analysis with live birth endpoints is implemented, then prediction accuracy improves with PPV and NPV of at least 60%, but the complexity of the analysis method increases
Solution Approach 1:
By segmenting the analysis to focus on specific exons rather than entire genes, the method achieves higher prediction accuracy through targeted measurement. The segmentation strategy reduces the data processing burden compared to comprehensive gene analysis, making the increased precision achievable without proportional increases in analytical complexity
Solution Approach 2:
The patent extracts and focuses on specific exons that are differentially expressed in competent oocytes, using live birth as the endpoint criterion. This extraction of key predictive exons simplifies the analysis compared to comprehensive gene expression profiling while maintaining high prediction accuracy through focused measurement of the most relevant genomic regions
Data Source
AI summary
Cumulus cell (CC) gene expression is being explored as an additional method to morphological scoring to choose the embryo with the highest chance to pregnancy. The present invention relates to a novel method of identifying biomarker genes for evaluating the competence of a mammalian oocyte in giving rise to a viable pregnancy after fertilization, based on the use of live birth and embryonic development as endpoint criteria for the oocytes to be used in an exon level analysis of potential biomarker genes. The invention further provides CC-expressed biomarker genes thus identified, as well as prognostic models based on the biomarker genes identified using the methods of the present invention.